tiprankstipranks
Advertisement
Advertisement

CHGCF Stock Latest News

Chugai Sets Terms for New Trust-Based Stock Compensation Plans
Company AnnouncementsChugai Sets Terms for New Trust-Based Stock Compensation Plans
5d ago
Chugai Results Reflected in Roche’s First-Quarter 2026 Sales Report
PremiumCompany Announcements
Chugai Results Reflected in Roche’s First-Quarter 2026 Sales Report
6d ago
CHGCF Earnings this Week: How Will it Perform?
PremiumPre-Earnings
CHGCF Earnings this Week: How Will it Perform?
7d ago
Chugai Clarifies Strategic Alliance and Governance Structure Under Roche Control
PremiumCompany Announcements
Chugai Clarifies Strategic Alliance and Governance Structure Under Roche Control
28d ago
Chugai Weighs Investment Unit Cut to Boost Liquidity and Broaden Investor Base
PremiumCompany Announcements
Chugai Weighs Investment Unit Cut to Boost Liquidity and Broaden Investor Base
1M ago
Chugai, Roche Halt Neuromuscular Trials of Emugrobart but Press On in Obesity
PremiumCompany AnnouncementsChugai, Roche Halt Neuromuscular Trials of Emugrobart but Press On in Obesity
1M ago
Chugai and Roche Advance NXT007 Into Phase III, Raising the Stakes in Hemophilia A
Premium
Company Announcements
Chugai and Roche Advance NXT007 Into Phase III, Raising the Stakes in Hemophilia A
2M ago
CHGCF
Chugai and Roche Advance NXT007 Into Phase III to Challenge Emicizumab in Hemophilia A
Premium
Company Announcements
Chugai and Roche Advance NXT007 Into Phase III to Challenge Emicizumab in Hemophilia A
2M ago
CHGCF
Chugai’s SAIL66 Phase I Completion: What the Latest Trial Update Means for Investors
PremiumCompany Announcements
Chugai’s SAIL66 Phase I Completion: What the Latest Trial Update Means for Investors
2M ago
CHGCF
Chugai to Replace Restricted Stock with Trust-Based Equity Incentive Plan
PremiumCompany Announcements
Chugai to Replace Restricted Stock with Trust-Based Equity Incentive Plan
3M ago
Chugai Pharmaceutical Plans Sharp Dividend Hike with 100th Anniversary Payout, Signals Normalization in 2026
PremiumCompany Announcements
Chugai Pharmaceutical Plans Sharp Dividend Hike with 100th Anniversary Payout, Signals Normalization in 2026
3M ago
Chugai’s 2025 Performance Reflected in Parent Roche’s Fiscal Results
PremiumCompany Announcements
Chugai’s 2025 Performance Reflected in Parent Roche’s Fiscal Results
3M ago
CHGCF Earnings this Week: How Will it Perform?
PremiumPre-EarningsCHGCF Earnings this Week: How Will it Perform?
3M ago
Chugai’s DONQ52 Celiac Study Advances, Adding a New Mid‑Stage Catalyst for CHGCF
Premium
Company Announcements
Chugai’s DONQ52 Celiac Study Advances, Adding a New Mid‑Stage Catalyst for CHGCF
4M ago
CHGCF
Chugai Pharmaceutical Completes Absorption-Type Merger of Renalys Pharma
Premium
Company Announcements
Chugai Pharmaceutical Completes Absorption-Type Merger of Renalys Pharma
4M ago
Chugai Highlights Positive Phase 3 Results and FDA Filing for Lilly’s Oral GLP-1 Orforglipron
PremiumCompany Announcements
Chugai Highlights Positive Phase 3 Results and FDA Filing for Lilly’s Oral GLP-1 Orforglipron
4M ago
Chugai Pharmaceutical to Merge with Renalys Pharma to Boost Kidney Disease Drug Development
PremiumCompany Announcements
Chugai Pharmaceutical to Merge with Renalys Pharma to Boost Kidney Disease Drug Development
5M ago
Chugai Pharmaceutical’s Promising Phase III Study on Ulcerative Colitis Treatment
PremiumCompany Announcements
Chugai Pharmaceutical’s Promising Phase III Study on Ulcerative Colitis Treatment
6M ago
CHGCF
Chugai Pharmaceutical Advances Satralizumab Trial for Autoimmune Encephalitis
PremiumCompany Announcements
Chugai Pharmaceutical Advances Satralizumab Trial for Autoimmune Encephalitis
6M ago
CHGCF
Chugai Pharmaceutical’s Satralizumab Study: A Potential Game-Changer for MOGAD Treatment?
PremiumCompany AnnouncementsChugai Pharmaceutical’s Satralizumab Study: A Potential Game-Changer for MOGAD Treatment?
6M ago
CHGCF
Chugai’s Phase III Study on Divarasib: A Potential Game-Changer in Lung Cancer Treatment
Premium
Company Announcements
Chugai’s Phase III Study on Divarasib: A Potential Game-Changer in Lung Cancer Treatment
6M ago
CHGCF
Chugai Pharmaceutical’s Promising Phase III Study on Crohn’s Disease Treatment
Premium
Company Announcements
Chugai Pharmaceutical’s Promising Phase III Study on Crohn’s Disease Treatment
6M ago
CHGCF

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >